Irbesartan/ Hydrochlorothiazide Aurobindo (Hydrochlorothiazide, Irbesartan)

Irbesartan/Hydrochlorothiazide is used in the management of cardiovascular conditions related to elevated blood pressure.

• Hypertension: reduces elevated systolic and diastolic blood pressure in adult patients.
• Essential hypertension: assists in reaching guideline‑recommended blood‑pressure targets when lifestyle measures alone are insufficient.
• Hypertension with fluid retention: combines vasodilatory and diuretic actions to control pressure and decrease excess extracellular fluid.

• Irbesartan selectively blocks angiotensin II type 1 (AT1) receptors, preventing vasoconstriction and aldosterone release, while hydrochlorothiazide inhibits sodium‑chloride reabsorption in the distal convoluted tubule, promoting diuresis and reducing plasma volume. The combined effect lowers systemic vascular resistance and cardiac preload, resulting in sustained blood‑pressure reduction.

Common Side Effects

• Dizziness or light‑headedness
• Headache
• Fatigue or weakness
• Increased urinary frequency
• Mild electrolyte disturbances (e.g., low potassium)
• Nausea or mild gastrointestinal upset

Serious or Rare Side Effects

• Severe dehydration or electrolyte imbalance
• Acute kidney injury or worsening renal function
• Hyperkalemia, especially with potassium‑sparing agents
• Angioedema or severe allergic reaction
• Marked hypotension leading to syncope
• Hepatic dysfunction or jaundice

Irbesartan/Hydrochlorothiazide should be used with careful clinical monitoring.

• Blood pressure monitoring: check regularly to avoid excessive hypotension.
• Renal function assessment: evaluate serum creatinine and eGFR before and during therapy.
• Electrolyte surveillance: monitor potassium and sodium levels, especially in patients on other diuretics.
• Hepatic impairment: use with caution in patients with liver disease.
• Hypersensitivity: discontinue if signs of rash, angioedema, or anaphylaxis appear.
• Store at ambient temperature: keep in the original container, protect from moisture and direct sunlight.

Irbesartan/Hydrochlorothiazide may interact with several medicines.

Major Interactions (Avoid)

• Aliskiren in diabetic patients: increased risk of renal impairment and hyperkalemia.
• Potassium‑sparing diuretics or supplements: may cause dangerous hyperkalemia.
• NSAIDs (e.g., ibuprofen, naproxen): can blunt antihypertensive effect and affect renal function.
• ACE inhibitors or other ARBs: combined use raises risk of kidney injury and hyperkalemia.
• Lithium: concurrent use can raise lithium levels and precipitate toxicity.

Moderate Interactions (Monitor Closely)

• Additional diuretics: additive hypotensive and electrolyte effects.
• Other antihypertensives (beta‑blockers, calcium channel blockers): may enhance blood‑pressure lowering.
• CYP2C9 inhibitors (e.g., fluconazole, amiodarone): may increase irbesartan plasma concentrations.
• Antacids containing aluminum or magnesium: can reduce absorption of irbesartan.
• Warfarin: monitor INR as diuretic‑induced fluid shifts may affect anticoagulation.